Annexin Pharmaceuticals is a Swedish privately held biotech company[1][2] developing new therapeutic approaches for inflammatory cardiovascular diseases. The concept for the therapy is based on the anti-inflammatory properties of Annexin A5, a body own protective protein that acts simultaneously against several key pathogenic mechanisms of cardiovascular diseases. The company is currently focusing on treatment of peripheral artery disease (PAD).

References

  1. ↑ Martz, Lauren (May 26, 2014). "Annexin: Attenuating vascular inflammation" (PDF). BioCentury: A18. Retrieved 1 February 2015.
  2. ↑ "Allabolag.se - Företagsinformation om alla Sveriges bolag".


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.